Oticon president satisfied with FDA approval: "A huge milestone"

An approval from the US FDA for Oticon Medical's cochlear implant system Neuro can help the Danish company kick down the door to the US market for several products. The US approval might also pave the way for the products to become accessible outside the US, President Jes Olsen states.

Photo: Jens Dresling

Thursday is a happy day for Danish company Demant's bone-anchored division Oticon Medical, which has received approval for the company's cochlear implant system Neuro by the US Food and Drug Administration (FDA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs